Protara Therapeutics, Inc. Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Protara Therapeutics, Inc. (TARA)
Company Research
Source: GlobeNewswire
NEW YORK, Feb. 02, 2026 (GLOBE NEWSWIRE) -- Protara Therapeutics, Inc. (Nasdaq: TARA) (“Protara” or the “Company”), a clinical-stage company developing transformative therapies for the treatment of cancer and rare diseases, today announced the recent grants of inducement non-qualified stock options and restricted stock units (RSUs) to one newly-hired employee. The Compensation Committee of Protara’s Board of Directors approved an aggregate of 10,200 stock option awards and 5,100 RSU awards to one new employee from the Inducement Plan, as inducements material to the new employee’s employment in accordance with Nasdaq Listing Rule 5635(c)(4). Such option awards were granted on February 2, 2026 and have an exercise price of $7.04 per share, Protara’s closing trading price on the grant date. Such RSU awards will have a grant date of April 1, 2026. All option awards vest over four years, with 25% of the underlying shares vesting on the one-year anniversary of the grant date and 1/36th
Show less
Read more
Impact Snapshot
Event Time:
TARA
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
TARA alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
TARA alerts
High impacting Protara Therapeutics, Inc. news events
Weekly update
A roundup of the hottest topics
TARA
News
- Protara Therapeutics (TARA) had its "buy" rating reaffirmed by TD Cowen.MarketBeat
- Protara Therapeutics Announces Fourth Quarter and Full Year 2025 Financial Results and Provides a Business Update [Yahoo! Finance]Yahoo! Finance
- Protara Therapeutics Announces Fourth Quarter and Full Year 2025 Financial Results and Provides a Business UpdateGlobeNewswire
- Protara Therapeutics (TARA) is now covered by JPMorgan Chase & Co.. They set an "overweight" rating and a $27.00 price target on the stock.MarketBeat
- Protara Therapeutics Highlights TARA-002 NMIBC Data, FDA Plans for Lymphatic Malformations at Oppenheimer Conf [Yahoo! Finance]Yahoo! Finance
TARA
Earnings
- 3/10/26 - Miss
TARA
Sec Filings
- 3/10/26 - Form 10-K
- 3/10/26 - Form 8-K
- 3/6/26 - Form 144
- TARA's page on the SEC website